(HELP)
NGM – Real vaqt narxi. Valyuta: USD
4.52
-0.13 (-2.80%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.56
+0.04 (0.88%)
Bozordan keyin: Mar 27, 2026, 7:57 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
4.52
-0.13 (-2.80%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.56
+0.04 (0.88%)
Bozordan keyin: Mar 27, 2026, 7:57 PM EDT
Cybin Inc., Helus Pharma nomi bilan faoliyat yurituvchi, psixiatriya sohasidagi klinik bosqichdagi kompaniya bo'lib, ruhiy kasalliklari bo'lgan bemorlar uchun psixodelik asosidagi terapevtik vositalarni ishlab chiqishga qaratilgan. Kompaniya katta depressiya (MDD)ni davolash uchun 3-bosqichli klinik sinovda bo'lgan psilosibinning deuterli analogi bo'lgan CYB003ni; va umumiy xavotir buzilishlarini davolash uchun 2-bosqichli klinik sinovda bo'lgan dimetiltriptaminning (DMT) deuterli analogi bo'lgan CYB004ni ishlab chiqadi. Kompaniya, shuningdek, mushak ichiga va tomir ichiga yuborish bo'yicha 1-bosqichli klinik sinovni yakunlagan deuterli DMT SPL028 in'ektsiyasini; MDD uchun SPL026ni; va markaziy asab tizimini davolash uchun preklinik bosqichda bo'lgan fenetilamin hosilasi bo'lgan CYB005ni ishlab chiqadi, shuningdek, tadqiqot qilinayotgan psixodelik asosidagi birikmalarning tadqiqot dasturiga ega. Kompaniya katta depressiya kasalligini davolashda CYB003ni baholaydigan ko'p millatli asosiy 3-bosqichli dasturi bo'lgan PARADIGMni qo'llab-quvvatlash uchun Segal Trials bilan strategik hamkorlik shartnomasiga ega. Kompaniya Kanadaning Toronto shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Mr. Aaron Bartlone | Chief Operating Officer |
| Mr. Eric So L.L.B. | Co-Founder, President & Executive Chairman |
| Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
| Mr. George Tziras | Chief Business Officer |
| Mr. Greg Cavers | Chief Financial Officer |
| Mr. John Kanakis | Co-Founder |
| Mr. Michael F. Cola |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | 6-K | cybininc-form6xk03x12x2026.htm |
| 2026-03-05 | 6-K | form6k.htm |
| 2026-01-12 | D |
| Chief Executive Officer |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer |